Nanotherapeutics relieve rheumatoid arthritis

Yang, Modi; Feng, Xiangru; Ding, Jianxun; Chang, Fei; Chen, Xuesi

doi:10.1016/j.jconrel.2017.02.032

Cited by 179 publications

(94 citation statements)

References 123 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By taking advantages of the inflamed articular microenvironment (acidic pH, hypoxia, energy over depletion, and overexpression of matrix metalloproteinases), stimuli‐responsive NMs can further ensure drug specificity and bioavailability while avoiding off‐target side effects. Employment of stimuli‐responsive NMs can offer extraordinary spatiotemporal control of both NMs accumulation and drug delivery at the RA sites in virtue of the ability to target the diseased tissues and respond to internal or external stimuli.…”

Section: Stimuli‐responsive Nms Overcome the Att Of Ra With Spatiotemmentioning

confidence: 99%

Move to Nano‐Arthrology: Targeted Stimuli‐Responsive Nanomedicines Combat Adaptive Treatment Tolerance (ATT) of Rheumatoid Arthritis

Liu

Guo

Liang

2018

Biotechnology Journal

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is one of the most popular chronic autoimmune diseases characterized with persistent synovial inflammation and bone destruction. Although considerable developments have been gained in clinical treatment of RA, the major drawback to RA therapy stems from the adaptive treatment tolerance (ATT) following the long-term drug use, which causes compromised efficacy, sustained drug dose increase, and severe adverse events. To address these challenges, it is of great significance to put forward innovative therapeutic approaches for RA treatment. Nowadays, developments of nanotechnology-based nanomedicines (NMs) for RA are in progress. Multifunctional NMs with targeted stimuli-responsive features have been one of the central concepts in designing more accessible formulations for efficient RA treatment. These NMs are able to postpone RA progression effectively, because of their delivery and on-demand release of medicaments at targeted sites in response to external or internal stimuli related to the RA pathophysiology without obvious adverse side-effects on the normal tissues. Therefore, NMs have gained interest from pre-clinical research scientists as well as clinical doctors worldwide. Herein, the authors highlight the recent attempts of targeted stimuli-responsive NMs for RA therapy in the last 5 years. The described progresses may pave the way to novel and highly effective RA NMs.

show abstract

Section: Stimuli‐responsive Nms Overcome the Att Of Ra With Spatiotemmentioning

confidence: 99%

Move to Nano‐Arthrology: Targeted Stimuli‐Responsive Nanomedicines Combat Adaptive Treatment Tolerance (ATT) of Rheumatoid Arthritis

Liu

Guo

Liang

2018

Biotechnology Journal

View full text Add to dashboard Cite

show abstract

“…Although chronic joint diseases differ in etiology and relative risk factors, symptoms, prognoses, and treatments, growing numbers of systemic administered drugs can be employed to manage, alone or in combination, the joint disorders [5]. Non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids (GCs), opioids, anti-rheumatic agents (i.e., methotrexate, hydroxychloroquine, sulfasalazine, and clodronate), and more recently biological agents (i.e., adalimumab, infliximab, and etanercept) are commonly used.…”

Section: Introductionmentioning

confidence: 99%

“…Hence, the reduced retention time of therapeutic agents in the targeted tissue requires frequent injections, which are associated with both risk of infection and/or joint disability and unsatisfactory patient compliance [4]. Additionally, repeated IA administrations of GCs could cause permanent damages to the articular cartilage, and systemic adverse events cannot be fully avoided; precautions should be observed in patients with concomitant diseases such as hypertension or diabetes mellitus [5,15]. …”

Section: Introductionmentioning

confidence: 99%

Intra-Articular Formulation of GE11-PLGA Conjugate-Based NPs for Dexamethasone Selective Targeting—In Vitro Evaluation

Chiesa

Pisani

Colzani

et al. 2018

IJMS

View full text Add to dashboard Cite

Selectively targeted nanoscale drug delivery systems have recently emerged as promising intravenously therapeutic option for most chronic joint diseases. Here, a newly synthetized dodecapeptide (GE11)-polylactide-co-glycolide (PLGA)-based conjugate was used to prepare smart nanoparticles (NPs) intended for intra-articular administration and for selectively targeting Epidermal Growth Factor Receptor (EGFR). GE11-PLGA conjugate-based NPs are specifically uptaken by EGFR-overexpressed fibroblast; such as synoviocytes; which are the primarily cellular component involved in the development of destructive joint inflammation. The selective uptake could help to tune drug effectiveness in joints and to decrease local and systemic side effects. Dexamethasone (DXM) is a glucorticoid drug commonly used in joint disease treatment for both systemic and local administration route. In the present research; DXM was efficiently loaded into GE11-PLGA conjugate-based NPs through an eco-friendly nanoprecipitation method set up for this purpose. DXM loaded GE11-PLGA conjugate-based NPs revealed satisfactory ex vivo cytocompatibility; with proper size (≤150 nm) and good dimensional stability in synovial fluid. Intra-articular formulation was developed embedding DXM loaded GE11-PLGA conjugate-based NPs into thermosetting chitosan-based hydrogel; forming a biocompatible composite hydrogel able to quickly turn from liquid state into gel state at physiological temperature; within 15 min. Moreover; the use of thermosetting chitosan-based hydrogel extends the local release of active agent; DXM.

show abstract

“…Currently, small-molecule disease-modifying anti-rheumatic drugs still serve as the first-line therapy. Besides, advances in understanding the pathogenesis of RA reveal more promising biological targets such as antibodies, cytokines, growth factors, and intracellular signaling molecules [2]. For instance, vobarilizumab, a nanobody consisting of an anti-IL-6R domain and an antihuman serum albumin domain, represented an exhilarating effect on RA in a phase 2b study [3].…”

Section: Introductionmentioning

confidence: 99%

Advanced nanomedicine for rheumatoid arthritis treatment: focus on active targeting

Chen

J.C.

Xiao

et al. 2017

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

Nanotherapeutics relieve rheumatoid arthritis

Cited by 179 publications

References 123 publications

Move to Nano‐Arthrology: Targeted Stimuli‐Responsive Nanomedicines Combat Adaptive Treatment Tolerance (ATT) of Rheumatoid Arthritis

Move to Nano‐Arthrology: Targeted Stimuli‐Responsive Nanomedicines Combat Adaptive Treatment Tolerance (ATT) of Rheumatoid Arthritis

Intra-Articular Formulation of GE11-PLGA Conjugate-Based NPs for Dexamethasone Selective Targeting—In Vitro Evaluation

Advanced nanomedicine for rheumatoid arthritis treatment: focus on active targeting

Contact Info

Product

Resources

About